The UNC HTPSA facility uses automated Fmoc Solid Phase Peptide Synthesis (SPPS) to make the synthetic peptides (the principles of Fmoc SPPS are described in References 1 and 2). We are routinely making 25-30-mer peptides. Usually 50-mer peptide synthesis is considered the upper limit for standard SPPS, but the real limits are highly dependent on the peptide sequence and a required purity level. Peptide homogeneity is evaluated by mass analysis (MALDI-TOF) and analytical HPLC. Usually we synthesize peptides on 10 to 100 µmol scale (~5 to 200 mg of crude peptide), but we can do a large scale synthesis if needed.
We specialize in synthesis of multiply modified peptides containing PTMs, unnatural amino acids, and fluorescent tags. Below are some of the peptide modifications we can introduce into your peptide sequence:
- acetylation (N-terminal or Lys(Ac))
- biotinylation (C-, N-terminal or Lys(Biot))
- methylation (on Lys or Arg residues)
- phosphorylation (on Ser, Thr, or Tyr residues)
- fluorescent tags and quenchers (e.g 5-Fam, 5-Tamra, BBQ-650)
- metal cations complexing tags (e.g., DOTA, NOTA)
- D- forms of amino acids
- unnatural amino acids (e.g. 6-Cl-Trp)
- amino acids containing stable isotopes (e.g. 2H, 13C, 15N)
- PEG linkers/spacers
We can also make Multiple Antigenic Peptides (MAPs) for polyclonal antibodies generation (see MAPs section for details). If we do not have a nonstandard (modified or unnatural) amino acid in the lab, we can order it (users will be charged for the price of the order). We have a capability to synthesize mid size libraries of crude peptides (~100 peptides in 2-3 weeks). We can print peptide microarrays (up to 4000 spots per slide) from synthesized peptides.
We would be happy to discuss your peptide needs and other modifications that you may require.
We obtain on-going support from the UNC Lineberger Comprehensive Cancer Center through the University Cancer Research Fund and the Cancer Center Support Grant. Consequently, publications supported by the UNC Center for Structural Biology must acknowledge NIH grant P30CA016086 and be submitted to PubMed Central in compliance with the NIH Public Access Policy.
Suggested acknowledgement: “This work was supported by the National Cancer Institute of the National Institutes of Health under award number P30CA016086. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”